The risk of invasive aspergillosis (IA) is considered to be low among autologous HSCT recipients, but an increase in the incidence has been observed recently in this setting. The aim of the study was to assess the influence of immunosuppressive drugs (steroids, rituximab, fludarabine, thalidomide), used in treatment of lymphoid malignancies during 6 months of pretransplant period, on IA incidence after autologous HSCT. A total of 109 patients with non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD) and multiple myeloma (MM), conditioned with carmustine, etoposide, cytarabine, melphalan or melphalan and transplanted with PBSC, were analyzed prospectively. Patients were monitored with twice-weekly galactomannan test. High-resolution computed tomograhy of the chest and bronchoscopy were performed in case of positive galactomanan test, persistent fever or pulmonary infiltrates. Documented IA was diagnosed in nine (8%) patients (three proven, six probable). The incidence of IA was comparable in NHL, HD and MM patients and not influenced by age, advanced disease or conditioning regimen. Factors significant for development of documented IA by univariate analysis were treatment with fludarabine (P ¼ 0.008) or rituximab (P ¼ 0.039). The only factor predicting documented IA by multivariate analysis was treatment with fludarabine (P ¼ 0.008). Patients treated with fludarabine or rituximab in pretransplant period are at risk of IA and require close monitoring and/or anti-mould prophylaxis.
Introduction
Invasive fungal infections are today the chief life-threatening infectious complications of transplant therapies. Candida and Aspergillus remain the leading fungal pathogens, but the incidence of invasive aspergillosis (IA) has increased significantly over the past decades. 1 The risk of IA among recipients of hematopoietic stem cell transplants (HSCT) is a function of neutropenia and/or immunodeficiency. The incidence rate of IA after allogeneic HSCT might exceed 20% with mortality ranging from 50 to 80%. 2, 3 In the autologous HSCT setting, the risk of IA is considered to be low, with incidence 2-6%, but an increase in IA rate in this group of patients has been reported recently. 1, 4 Changes in the population at risk for IA due to intensified and new treatment strategies require continuous reevaluation of the risk factors for IA, also among autologous transplant recipients.
We report a prospective study of the incidence and risk factors of IA in patients with lymphoid malignancies treated with autologous HSCT with respect to the therapy performed during 6 months of pretransplant period.
Design and methods
Patients and study design A total of 109 consecutive adult patients, with nonHodgkin's lymphoma (NHL), Hodgkin's disease (HD) or multiple myeloma (MM) were analyzed prospectively between January 2005 and September 2007. All patients received their first transplant with high-dose therapy (HDT) followed by the infusion of hematopoietic stem cells derived from blood (PBSC). Patients differed in stage of disease, type of treatment, response to treatment and number of chemotherapy lines before HSCT. Their characteristics are shown in Table 1 . Throughout the study, patients were evaluated for the development IA during neutropenia after HDT until neutrophil recovery. Mortality was analyzed up to 100 days post transplant. In addition to defined risk factors for IA (prolonged neutropenia, use of steroids, older age, advanced stage of disease) the influence of pretransplant treatment on IA incidence was analyzed. The study was approved by the Local Bioethical Committee.
Transplant procedures
PBSC were mobilized and collected after chemotherapy followed by recombinant G-CSF. ) per kg of CD34 þ cells.
Prophylaxis of infection
All analyzed patients received a low-germ diet and were treated in a separate transplantation ward in single rooms with high-efficiency particulate air filtration. Intensified hygiene measures in transplant unit included: masks, gloves and gowns for staff; visitors were not allowed to enter the unit. Water and air were microbiologically tested every 2 weeks and every 3 months, respectively. Prophylactic antibiotics included norfloxacin or ciprofloxacin and fluconazole until neutrophil recovery or administration of antimicrobial therapy due to infection.
Definitions and diagnostic criteria
Severe and very severe neutropenia were defined by the peripheral blood ANC below 0.5 Â 10 9 and 0.1 Â 10 9 per l, respectively. Neutrophil engraftment was defined as the first of 2 consecutive days on which the ANC exceeded 0.5 Â 10 9 per l after transplantation. Primary graft failure was determined when no engraftment was achieved by day þ 21.
All patients were screened with biweekly galactomannan (GM) test during neutropenia period. Assays were performed on peripheral blood serum in accordance with the manufacturer's specifications (Platelia Aspergillus EIA; Bio-Rad Laboratories, Marnes-la-Coquette, France). According to the producer's recommendations, samples were considered to be positive with index of X0.5 and negative with index o0.5. Two consecutive positive results for the presence of GM suggested IA. 5 All GM results were analyzed carefully to exclude false positive and false negative ones, caused by various factors. 6 GM X0.5 was considered to be false positive if no clinical or radiological data supported IA. GM o0.5 was considered to be false negative in case of microbiologically proven IA.
Fever was defined as a single temperature 438.3 or X38 1C over at least 1 h. Infections during neutropenia were classified as microbiologically documented infection, when a pathogenic microorganism was recovered; clinically documented infection with the presence of signs and symptoms of inflammation at anatomic sites and nonrecovered pathogen; fever of unknown origin (FUO) in case of fever without a localized source of infection or identified pathogen. The diagnosis of IA was made according to European Organisation for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/ MSG) criteria as proven, probable and possible. 7 In the event of fever, patients were evaluated by physical examination. Blood cultures from the catheter, the peripheral vein, and cultures from suspected sites were taken. This procedure was repeated daily if fever persisted and in case of any new febrile episode. Febrile patients were immediately treated with empirical antibiotic therapy according to the approved guidelines, described previously. 4, 8 If etiology of infection was identified, targeted antibiotic therapy was started. Documented IA (proven and probable) were treated with voriconazole or liposomal amphothericin B. Patients with possible IA received empirical treatment with amphotericin B deoxycholate.
IA were suspected in case of persistent fever X7 days of broad spectrum antibiotic treatment; GM index X0.5 in two consecutive samples; in cases of any clinical symptoms of invasive fungal infection or in case of pulmonary infiltrates in chest radiography. The diagnostic work-up and evaluation included chest high-resolution computed tomography (HRCT), followed by bronchoalveolar lavage (BAL) and/or biopsy for microbiological cultures, when possible. 9 Computed tomography of central nervous system (CNS) or sinuses was performed in case of clinical suspicion of CNS (for example focal neurological symptoms, persistent headache, mental changes, meningeal irritation) or sinonasal (for example nasal discharge, epistaxis, face or periorbital swelling, nasal mucosa ulceration or necrotic lesions) infections.
The 6-month past history preceding HSCT of all patients was analyzed with respect to treatment with potentially immunosuppressive drugs: thalidomide, fludarabine and rituximab. Steroid therapy was taken into consideration in case of cumulative dose of 600 mg per month of prednisone or an equivalent drug. 10 Comorbidities and conditions significant for development of IA, such as chronic pulmonary disease, diabetes mellitus, history of previous IA, were analyzed. Cox proportional hazard regression model was used to correlate each potential prognostic factor with an occurrence of first day of diagnosis of specific infection in univariate analysis. The factors that appeared to be important were then fitted together, and dropped one at a time in a backward stepwise manner using a likelihood ratio test at a 0.05 level until all factors in the model were significant. All tests were two-sided with P-value of 0.05 being considered as significant.
Results
Hematological recovery and duration of neutropenia Neutrophil recovery occurred in 107 patients at day 14 (range; 10-54). Two patients died before hematologic reconstitution due to septic shock caused by Pseudomonas aeruginosa. There were no significant differences in length of severe and very severe neutropenia among patients with NHL, HD and MM. Delayed neutrophil recovery 421 days was seen in 11 patients and was not related to age, sex, diagnosis, stage of disease, treatment before transplantation, conditioning and number of grafted cells. Patients with HD were generally younger, and transplanted with lower number of CD34 þ cells per kg body weight (Table 2 ).
Incidence and characteristic of infection
Infectious complications during neutropenia occurred in 99 (90.8%) patients. Patients with FUO accounted for 67% (67/99), with response to first line empirical antibiotic treatment in 32 (32%) cases. Bacterial infections were proven in 20 (20%) patients as bacteremia (n ¼ 19) and urinary tract infection (n ¼ 1). Gram-positive bacteria caused infection in 13 patients, Gram negative in 4 patients, and 3 patients had polymicrobial bacteremia. One patient was diagnosed with invasive Candida albicans infection. Clinically documented infections were diagnosed as neutropenic enterocolitis in two patients with response to empirical therapy with carbapenems.
Documented IA was diagnosed in nine (8%) patients as proven in three cases and probable in six cases, all with lung involvement. Possible IA was established in 35 (35%) patients. GM test was performed with median 4 (range: 2-12) number of samples per patient. Positive results were achieved in eight cases. In two patients treated with piperacillin/tazobactam without clinical and radiological data supporting IA, GM 40.5 was considered to be false positive (according to Viscoli et al. 12 ). In one case with proven IA, GM o0.5 was considered to be false negative (according to Kedzierska et al. 6 ). HRCT was performed in 19 patients and revealed typical halo sign in 2 patients, ground-glass attenuation in 4 and nodules in 3 cases. Bronchoscopy with BAL and biopsy were performed in 22 patients. Endobronchial biopsy revealed Aspergillus fumigatus in three cases.
Risk factors analysis
The median time to diagnosis of documented IA was 10 (range: 6-24) days. The incidence of documented IA was comparable in patients with NHL, HD and MM and was not influenced by age, conditioning regimen and advanced disease stage. The highest incidence of documented IA was observed in patients treated with fludarabine (3/9 vs 6/100; P ¼ 0.025) or rituximab (5/27 vs 4/82; P ¼ 0.040).
Analysis of risk of IA was performed in Cox model for the following factors: sex, age, diagnosis, advanced stage of disease, conditioning regimen, CD34 þ cell dose, length of severe and very severe neutropenia, use of steroids, thalidomide, rituximab, fludarabine. Factors significant for development of documented IA by univariate analysis were treatment with fludarabine (P ¼ 0.008, hazard ratio, HR ¼ 6.5, 95% CI ¼ 1.6-25) and treatment with rituximab (P ¼ 0.039, HR ¼ 4.0, 95% CI ¼ 1.6-14.9; Table 3 ). The only factor predicting documented IA by multivariate analysis was treatment with fludarabine (P ¼ 0.008, HR ¼ 6.5, 95% CI ¼ 1.6-25).
Comorbidities significant for development of IA, such as chronic pulmonary disease or diabetes mellitus were not present and no history of previous IA was found in analyzed group.
Survival
Five patients (4.5%) died within 100 days after transplant. Two (1.8%) patients died during neutropenia due to septic shock caused by P. aeruginosa. Three patients died after hematologic recovery: IA was considered the primary cause of death in 1 patient and the contributory factor in another one. Both cases of IA were diagnosed during neutropenia as IA proven and IA probable. One death on 42 day was related to cardiotoxicity. Invasive aspergillosis after autologous HSCT L Gil et al
Discussion
An increasing incidence of IA among allogeneic transplant recipients, including those with GVHD, has focused our attention on other groups of immunocompromised individuals. Patients with lymphoid malignancies display multiple cellular and humoral immunodeficiencies, which increase with both conventional therapy and HDT, and constitute an important predisposing factor for opportunistic infections. To our knowledge, this is the first prospective study of incidence and risk factors of IA during neutropenia after HDT and autologous HSCT among patients with lymphoid malignancies with a history of treatment with immunosuppressive drugs, such as steroids, fludarabine, rituximab or thalidomide. Throughout the whole study, complex and uniform infectious surveillance strategy and prophylaxis was undertaken. In this single-center analysis proven and probable IA occurred in 8% patients. Although an increasing rate of IA among autologous transplant recipients over the years has been reported by several groups, the reason for this trend is not entirely clear. 1, 13 Historical data were likely to underestimate the risk of IA, both after allogeneic and autologous HSCT, because of inadequacies in diagnosis. Today, improved diagnosis of Aspergillus infections, including HRCT and GM Ag detection, has apparently increased the number of IA cases. 14, 15 Knowledge of epidemiological and clinical features of IA is important for prophylactic strategies, as well as for the use of antifungal therapy including empirical treatment.
One of the most important determinants for IA is prolonged neutropenia, and its duration of more than 21 days increases the risk of IA significantly. 16 With the development of autologous transplantation with peripheral stem cells and the use of G-SCF, the duration of neutropenia is usually less than 14 days, so this practice diminishes the risk of IA in this setting. A higher incidence is observed in patients receiving BM stem cells instead of PBSC. 13 Identified risk factors for IA in transplant settings include also: age 440 years, underlying diagnosis, advanced disease, receipt of HSCT from an HLA-mismatched or unrelated donor and GVHD. 1 It has also been proven that high cumulative doses of corticosteroids or continuous corticosteroid therapy are associated with both risk of acquisition and poor outcome of IA. 11, 17 Our study concerned a homogenous population of patients with lymphoid malignancies, mainly with advanced stage of disease. Although advanced disease is an important risk factor for IA, we found no statistical significance for this factor.
In eight of nine patients with established IA, BEAM modified with dexamethasone was used as preparative regimen. The short median time to IA diagnosis could indicate the influence of dexamethasone on its development, but we did not document any impact of conditioning regimen on IA risk.
We found no influence of age, number of CD34 þ cells and duration of neutropenia on IA risk in analyzed cohort of patients. The incidence of IA was nonsignificantly more often in patients with NHL, than with MM or HD. Higher rate of infections, with wide range of causative pathogens, among NHL patients after autologous HSCT has been described earlier, however an increased occurrence of IA in nongrafted and grafted patients with MM has also been reported. 1, 16, [18] [19] [20] Our analysis documented however an influence of pretransplant fludarabine or rituximab treatment on IA risk, although no impact of steroids and thalidomide was found.
Fludarabine-based combination therapy regimens are highly effective in the treatment of patients with indolent lymphoproliferative disorders. However, the use of this powerful immunosuppressant causing a prolonged effects on lymphopoiesis and a medium-term myelosuppression, alters the spectrum of infection in treated patients to include both bacterial infections, as well as opportunistic infection (Listeria, Candida, Aspergillus, Pneumocystis, mycobacterial infections and herpesviruses). [21] [22] [23] [24] The pathogenesis of these infection is related to the quantitative and qualitative T-cell abnormalities induced by fludarabine. A significant decline in the peripheral blood T-cell level occurs early during therapy, with greater impact on CD4 þ than on CD8 þ or natural killer cells, which may persist for 1-2 years after discontinuation of therapy. 25 Recent studies have also shown prominent depletion of normal B-cells, altered B-cell maturation and severe hypogammaglobulinema. 26 Severe infections occur in up to one-third of patients treated with fludarabine. High incidence of infections is observed especially in patients treated with the combination of fludarabine and rituximab. Several risk factors for infections related to fludarabine therapy have been identified: concurrent corticosteroid therapy, advanced disease stage, baseline neutropenia and older age. 27 These factors could also contribute in an increased IA risk in our study. Patients with NHL were conditioned with modified BEAM regimen including dexamethasone. The combined impact of dexamethasone and fludarabine on the immune system might be involved in IA development in this subgroup of patients. In autologous transplant recipients however, a higher incidence of late infections has been observed in patients with a history of fludarabine treatment. 19 Rituximab, a chimeric MoAb directed against CD20, is now part of the standard treatment for CD20-expressing B-cell NHL. Rituximab depletes peripheral B cells and causes variable suppression of serum Igs, and it may increase the frequency of severe neutropenia when administered with chemotherapy. 28 Rituximab when used with standard treatment for NHL does not appear to influence the incidence of infectious complications. However, significantly higher rates of opportunistic infection and infection-related deaths are documented in subgroups of patients treated with rituximab, who are already immunocompromised. 29 The role of B lymphocytes extends beyond production antibodies, as they are competent APCs and produce cytokines, activating and altering the function of Th lymphocytes. 30 Effective immunity requires Th-cellmediated responses, and B lymphocyte depletion might reduce protection against Aspergillus infection.
31 For the present, there are insufficient data to draw any inference on the precise influence of B lymphocytes on Th-cell-mediated immunity against Aspergillus infection in humans.
Thalidomide in combination with dexamethasone is today a standard first-line treatment regimen in multiple myeloma patients. An immunosuppressive activity of thalidomide by inhibiting the tumor necrosis factor-a production by activated monocytes has been described and, in some instances, serious infectious complications have been reported. However, analysis of immune parameters in multiple myeloma patients treated with thalidomide in combination with conventional chemotherapy revealed no associated significant humoral or cellular immunodeficiencies in comparison with patients receiving chemotherapy alone. 32 Thalidomide therapy preceding autologous HSCT seems not to influence the infection profile in that setting.
In our analysis, infectious complications during neutropenia occurred in 90.8% and this corresponds to other reports, whereas lower rates of infection (35-75%) have also been published. 33, 34 A substantial incidence of febrile complications was reported by many centers, regardless of antimicrobial prophylaxis. 34, 35 Delayed neutrophil recovery and prolonged neutropenia that might be involved in the incidence of infections, were diagnosed in 11 patients and were not related to age, sex, diagnosis, stage of disease, treatment before transplantation, conditioning or number of grafted cells.
The early treatment related mortality in our analysis was 4.5% and was similar to reports from other study groups. 20 Infections were the main cause of death in 4 (3.6%) patients. Seven of nine patients with documented IA were cured with targeted antifungal therapy, which confirms the relatively good outcome for autologous transplant recipients who are diagnosed with invasive fungal infection. 36 Though the epidemiology of invasive fungal infection is center-dependent, we identified groups of patients at high risk of IA during neutropenia after HDT and autologous HSCT. Patients treated with fludarabine or rituximab in pretransplant period are at high risk of IA and require close monitoring based on HRCT and GM tests and/or antimould prophylaxis.
